MEDIMMUNE EVALUATES NORWOOD VIROSOMAL VACCINE
July 18th 2008 22:26
Thursday July 17, 2008
Daily news on ASX-listed biotechnology companies
* ASX, BIOTECHS UP: BIONOMICS UP 10%, UNIVERSAL BIO DOWN 6%
* MEDIMMUNE EVALUATES NORWOOD VIROSOMAL VACCINE
* HALCYGEN COMPLETES PHASE III SUBA-ITRACONAZOLE DOSING
* VIRALYTICS UNVEILS ITS NEW DIRECTIONS
* SIX PRANA SCIENTISTS TAKE PBT2 TO CHICAGO CONFERENCE
* LIVING CELL HOSTS DIABETES CONFERENCE
* BRAINZ DIRECTOR DR ROBIN COSGREVE RESIGNS
* FMR FIDELITY CORRECT HEARTWARE HOLDING
subscribe to Biotech Daily at the link above or at www.biotechdaily.com.au
NORWOOD IMMUNOLOGY, NORWOOD ABBEY, ASTRAZENECA
Astrazeneca’s Medimmune will evaluate the virosomal vaccine technology for respiratory syncytial virus developed by Norwood Immunology’s Virosomal Biological.
Medimmune is 100 percent owned by the Astrazeneca Group and Virosomal Biological is a wholly-owned subsidiary of Norwood Immunology.
Norwood Immunology chief scientific officer Prof Richard Boyd told Biotech Daily that Medimmune would pay an “undisclosed sum” for the rights to the virosomal vaccine.
He said a virosome was a virus with the genetic material removed.
“Virosomes are produced in a highly active form supercharged with immune-enhancing molecules giving up to 150-fold response compared to other treatments,” Prof Boyd said.
Prof Boyd said virosomal vaccines were a platform technology and Medimmune was specifically investigating its use for respiratory syncytial virus.
In a media release to the ASX from Norwood Abbey, Norwood Immunology said it had agreed to an exclusive collaboration period with Medimmune of six months in exchange for an exclusivity fee and the reimbursement of costs associated with performing collaborative research programs using Medimmune vaccine candidates and the group's virosome technology.
Norwood Immunology chief executive officer Richard Williams said the agreement was indicative of the attractiveness of the Virosomal Biological's adjuvanted virosome technology to major vaccine partners.
“We look to build on this second vaccine partnership with a major pharmaceutical company and anticipate seeking partners for our preclinical package for herpes simplex virus in the second half of 2008,” Mr Williams said.
The publicly listed Norwood Abbey holds 48.6 million shares or 21 percent of the unlisted Norwood Immunology.
Norwood Abbey was up 0.1 cents or 6.25 percent to 1.7 cents.
subscribe to Biotech Daily at the link above or at www.biotechdaily.com.au
| 15 |
| Vote |
Shared on
Add To: 
Subscribe to this blog
